Ambry Names Tom Schoenherr as Chief Commercial Officer
December 14 2017 - 5:04AM
Business Wire
Advancing Precision Medicine and Expanding
Ambry’s Genetic Testing into Global Markets
Ambry Genetics Corporation (Ambry), leaders in genetic testing,
announced today Tom Schoenherr will serve as Ambry’s new Chief
Commercial Officer (CCO). Tom’s primary role will be to build upon
Ambry’s success in the genetic testing space following the
successful acquisition by Konica Minolta.
This press release features multimedia. View
the full release here:
http://www.businesswire.com/news/home/20171214005106/en/
New Ambry CCO Tom Schoenherr (Photo:
Business Wire)
Tom Schoenherr brings more than 20 years of commercial
experience in molecular diagnostics with a solid track-record for
building high-growth companies. Mr. Schoenherr previously led
Counsyl's commercial strategy, and was responsible for driving
business growth and increasing market share in the very competitive
carrier screening space. He also served in similar roles at Quest,
Siemens Healthcare and Abbott Diagnostics.
“We are very excited to have Tom on board to lead our commercial
team; he brings a great mixture of sales management, leadership and
energy,” says Ambry CEO Dr. Aaron Elliott. “In our partnership with
Konica Minolta, Ambry is identifying new market opportunities in
the pursuit of precision medicine. We believe Tom is the right
person to lead that charge.”
As Ambry’s Chief Commercial Officer, Mr. Schoenherr will be
responsible for the execution of Ambry’s commercial strategy by
overseeing all commercial sales, including business development,
client services, genetic specialists and marketing. Mr. Schoenherr
will build upon Ambry’s reputation for top quality testing and
scientific innovation to lead new market expansion both domestic
and globally as a part of Ambry’s growth strategy.
Konica Minolta closed its acquisition of Ambry late October with
a mission to combine their existing capabilities in medical
imaging, including its high-sensitivity tissue testing
immunostaining technology (HSTT), with Ambry’s advanced genetic
testing to advance precision medicine.
“We look forward to Tom joining the team to build a commercial
organization focused on bringing important research and
comprehensive testing to patients,” said Kiyotaka Fujii, President
of Global Healthcare, Konica Minolta. “We are certain that the
combination of our precise medical imaging, along with Ambry’s
expertise in genetic testing will enhance patient care and preserve
quality of life.”
“I am excited to be a part of this industry-changing global
healthcare dynasty, committed to advancing science and developing
breakthrough technologies,” says Mr. Schoenherr. “After pioneering
carrier screening at Counsyl, I am excited to propel Ambry to the
top of the genetic testing industry.”
About Ambry
Ambry Genetics is both College of American Pathologists
(CAP)-accredited and Clinical Laboratory Improvement Amendments
(CLIA)-certified. Ambry is an established leader in clinical
genetic diagnostics and genetics software solutions, combining both
to offer the most comprehensive testing menu in the industry. Ambry
has established a reputation for sharing data while safeguarding
patient privacy, unparalleled service, and responsibly applying new
technologies to the clinical molecular diagnostics market. For more
information about Ambry Genetics, visit ambrygen.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171214005106/en/
Ambry Genetics CorporationAaron Schmidt, Sr. Manager,
Communications949.457.4679aschmidt@ambrygen.com